Hub : Traits :

Asthma

691 significantly associated models · 157 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	7686056	11137778	6	2	1.9e-09	3.2e-09	1.8e-01	95	KIF1B RERE
2	1	151313774	152991060	3	6	1.4e-11	1.0e-12	1.0e+00	100	FLG LINGO4 S100A11
3	1	166702558	168182443	1	1	5.0e-13	2.4e-13	1.0e+00	100	CD247
4	1	172905751	173423799	1	1	6.9e-08	9.1e-08	1.0e+00	100	TNFSF4
5	1	202317696	203743653	2	1	8.8e-10	1.4e-09	1.0e+00	100	MYBPH
6	2	99922967	100994580	1	1	2.5e-08	2.2e-08	7.3e-02	90	AFF3
7	2	101994731	104027106	6	8	8.4e-62	5.1e-51	NaN	NaN	IL18R1 IL1R1 IL1RL1 SLC9A2
8	2	241941773	243048760	8	3	3.2e-23	8.6e-24	3.2e-01	99	D2HGDH ING5
9	3	127622736	128373556	1	1	4.1e-08	2.5e-07	4.0e-01	97	EEFSEC
10	4	38097478	39643536	4	1	2.7e-14	2.1e-15	3.7e-03	87	TLR1
11	4	122377715	123976639	1	1	1.4e-17	1.1e-14	5.0e-03	87	KIAA1109
12	5	35608310	36124514	1	1	1.2e-08	7.0e-09	1.0e+00	100	IL7R
13	5	109381583	111527482	5	8	2.8e-23	4.2e-38	NaN	NaN	SLC25A46 TMEM232 TSLP WDR36
14	5	130588008	132900729	15	7	1.4e-23	7.4e-26	NaN	NaN	AC034220.3 KIF3A P4HA2-AS1 SLC22A5
15	5	140789933	142230251	1	1	1.6e-09	1.1e-09	7.3e-03	81	NDFIP1
16	5	156009720	157697754	2	1	4.0e-10	4.5e-09	1.9e-02	84	ADAM19
17	6	25266147	26682323	1	2	1.8e-07	4.0e-09	2.2e-04	61	TRIM38
18	6	34528785	35950210	2	1	2.4e-08	1.0e-09	6.6e-03	80	ZNF76
19	6	63986735	64534000	1	1	1.7e-08	5.2e-09	5.9e-02	90	PTP4A1
20	6	89941356	91704536	1	2	2.5e-16	2.0e-24	3.4e-06	79	BACH2
21	6	134905567	136516257	2	2	5.6e-14	3.3e-09	7.7e-01	100	AHI1
22	7	27623776	28468319	1	1	2.6e-07	2.2e-12	1.5e-06	53	JAZF1
23	9	4934896	7345375	5	3	2.3e-28	1.1e-56	1.2e-22	62	GLDC KIAA1432 RANBP6
24	10	74879374	76266883	1	1	1.5e-07	2.2e-05	2.1e-01	91	RP11-574K11.5
25	10	93657148	95110026	1	1	7.5e-08	1.8e-08	1.4e-02	81	KIF11
26	11	60839578	62346131	6	1	2.5e-10	3.3e-10	6.2e-02	91	FADS1
27	11	64845438	66919278	5	2	5.3e-09	3.0e-10	5.9e-05	59	CTD-3074O7.5 EFEMP2
28	11	75678647	77536441	2	1	1.4e-26	3.4e-45	1.4e-21	54	LRRC32
29	11	110776537	112287801	1	1	1.3e-09	1.7e-10	1.0e+00	100	SIK2
30	12	47407397	48825686	1	1	2.9e-07	6.0e-06	1.0e-02	68	RP1-197B17.3
31	12	55601472	58677299	12	4	4.1e-16	2.8e-25	1.2e-03	90	GPR182 KIF5A RPS26 STAT6
32	12	120502726	122037099	1	1	9.2e-09	8.4e-08	6.8e-02	88	SPPL3
33	13	99047988	100728229	3	3	3.8e-14	2.2e-17	5.4e-02	95	UBAC2
34	14	92733536	93401178	1	1	2.6e-09	1.6e-05	8.2e-02	84	RIN3
35	15	66662107	68789191	4	4	3.6e-32	2.6e-37	3.5e-04	92	IQCH SMAD3
36	16	10325245	12010444	5	2	1.1e-19	1.4e-26	1.7e-06	80	CLEC16A RP11-396B14.2
37	16	26518263	28065536	5	2	2.4e-13	2.6e-12	9.1e-04	78	CTD-3203P2.1 IL4R
38	17	36710513	39068227	23	9	1.2e-49	3.6e-48	1.0e+00	100	C17orf37 CASC3 GSDMA KRT222 MED24 ORMDL3
39	17	42624404	43570226	1	1	1.0e-08	1.1e-08	1.1e-02	80	CTD-2020K17.3
40	17	46668951	48139500	2	1	1.5e-14	9.5e-16	6.0e-03	88	ZNF652
41	19	15771809	17268784	1	1	3.0e-07	9.0e-06	3.4e-03	56	EPS15L1
42	19	45585167	46994833	3	1	5.0e-09	5.0e-10	1.0e+00	100	DMWD
43	20	62024275	62614338	2	1	1.3e-08	1.1e-06	8.7e-01	100	STMN3
44	22	41071659	42685537	5	1	6.4e-08	1.1e-07	4.1e-01	98	PHF5A

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Allergy	30.96	64	53	117.8	-0.97	1.9e-53	AC034220.3 AFF3 AHI1 BACH2 C17orf37 CASC3 CD247 CLEC16A CTD-2020K17.3 CTD-3074O7.5 CTD-3203P2.1 D2HGDH EEFSEC EFEMP2 EPS15L1 FADS1 FLG GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R ING5 IQCH JAZF1 KIAA1109 KIAA1432 KIF11 KIF1B KIF3A KIF5A KRT222 LINGO4 LRRC32 MED24 NDFIP1 ORMDL3 P4HA2-AS1 PHF5A RANBP6 RERE RIN3 RP11-396B14.2 RP11-574K11.5 RPS26 S100A11 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 STMN3 TLR1 TMEM232 TNFSF4 TSLP UBAC2 WDR36 ZNF652
Asthma (self-reported)	30.54	71	69	153.3	1.00	5.7e-153	AC034220.3 ADAM19 AFF3 AHI1 BACH2 C17orf37 CASC3 CD247 CLEC16A CTD-2020K17.3 CTD-3074O7.5 CTD-3203P2.1 D2HGDH DMWD EEFSEC EFEMP2 EPS15L1 FADS1 FLG GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R ING5 IQCH JAZF1 KIAA1109 KIAA1432 KIF11 KIF1B KIF3A KIF5A KRT222 LINGO4 LRRC32 MED24 MYBPH NDFIP1 ORMDL3 P4HA2-AS1 PHF5A PTP4A1 RANBP6 RERE RIN3 RP11-396B14.2 RP11-574K11.5 RP1-197B17.3 RPS26 S100A11 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 STMN3 TLR1 TMEM232 TNFSF4 TRIM38 TSLP UBAC2 WDR36 ZNF652 ZNF76
Respiratory disease	30.22	68	61	135.6	1.00	1.7e-94	AC034220.3 ADAM19 AHI1 BACH2 C17orf37 CASC3 CD247 CLEC16A CTD-2020K17.3 CTD-3074O7.5 CTD-3203P2.1 D2HGDH DMWD EEFSEC EFEMP2 FADS1 FLG GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R ING5 IQCH JAZF1 KIAA1109 KIAA1432 KIF11 KIF1B KIF3A KIF5A KRT222 LINGO4 LRRC32 MED24 MYBPH NDFIP1 ORMDL3 P4HA2-AS1 PHF5A PTP4A1 RANBP6 RERE RIN3 RP11-396B14.2 RP11-574K11.5 RP1-197B17.3 RPS26 S100A11 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 STMN3 TLR1 TMEM232 TNFSF4 TSLP UBAC2 WDR36 ZNF652 ZNF76
Blood Eosinophil Count	28.26	50	47	104.4	0.91	3.6e-27	AC034220.3 AHI1 BACH2 C17orf37 CASC3 CD247 CLEC16A CTD-3203P2.1 D2HGDH DMWD EFEMP2 FADS1 GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R ING5 IQCH KIAA1109 KIAA1432 KIF11 KIF1B KIF3A KRT222 LRRC32 MED24 NDFIP1 P4HA2-AS1 PHF5A RANBP6 RERE RIN3 RP11-396B14.2 RPS26 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 TMEM232 TSLP UBAC2 WDR36 ZNF652
Allergy or Eczema	27.10	54	44	97.8	0.93	3.3e-33	AHI1 BACH2 C17orf37 CASC3 CD247 CLEC16A CTD-3203P2.1 D2HGDH EFEMP2 FLG GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R ING5 IQCH JAZF1 KIAA1109 KIAA1432 KIF3A KRT222 LINGO4 LRRC32 MED24 NDFIP1 ORMDL3 P4HA2-AS1 PHF5A RANBP6 RERE RIN3 RP11-396B14.2 RP11-574K11.5 RPS26 S100A11 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 STMN3 TLR1 TMEM232 TNFSF4 TSLP UBAC2 WDR36 ZNF652
Hayfever, allergic rhinitis or eczema	24.11	50	40	88.9	0.94	1.4e-32	AHI1 BACH2 C17orf37 CD247 CLEC16A CTD-3203P2.1 D2HGDH EFEMP2 FLG GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R JAZF1 KIAA1109 KIAA1432 KIF3A KRT222 LINGO4 LRRC32 MED24 NDFIP1 ORMDL3 P4HA2-AS1 PHF5A RANBP6 RERE RIN3 RP11-396B14.2 RPS26 S100A11 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 STMN3 TLR1 TMEM232 TNFSF4 TSLP UBAC2 WDR36 ZNF652
Blood White Count	13.68	24	15	33.3	0.61	1.9e-04	AC034220.3 AHI1 BACH2 CASC3 CLEC16A EFEMP2 EPS15L1 FADS1 GSDMA IL1RL1 KIF1B KIF3A MED24 NDFIP1 ORMDL3 P4HA2-AS1 RERE RIN3 RP11-396B14.2 SLC22A5 SPPL3 STMN3 ZNF652 ZNF76
Medication: Ventolin 100micrograms inhaler	12.91	28	7	15.6	0.99	3.4e-30	AFF3 AHI1 BACH2 CD247 CLEC16A CTD-2020K17.3 D2HGDH GLDC GPR182 IL18R1 IL1RL1 ING5 IQCH KIAA1109 KIAA1432 LINGO4 LRRC32 NDFIP1 ORMDL3 RANBP6 RPS26 SLC22A5 SLC9A2 SMAD3 STAT6 TLR1 TSLP ZNF652
Hayfever/allergic rhinitis (self-reported)	12.61	27	15	33.3	0.97	1.3e-22	BACH2 C17orf37 CD247 CLEC16A D2HGDH GLDC GPR182 IL18R1 IL1RL1 IL7R KIAA1109 KIAA1432 KRT222 LRRC32 ORMDL3 RANBP6 RP11-396B14.2 RPS26 SLC25A46 SLC9A2 SMAD3 STAT6 TLR1 TMEM232 TNFSF4 TSLP WDR36
Wheeze or whistling in the chest in last year	12.16	36	17	37.8	0.99	1.9e-37	ADAM19 AFF3 BACH2 CASC3 CD247 CLEC16A D2HGDH DMWD GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 ING5 JAZF1 KIAA1109 KIAA1432 LINGO4 LRRC32 MED24 ORMDL3 RERE RIN3 RP11-396B14.2 RP11-574K11.5 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 STMN3 TSLP UBAC2 WDR36 ZNF652
Medication: Seretide 50 evohaler	6.61	8	1	2.2	0.98	1.2e-10	BACH2 D2HGDH IL18R1 IL1RL1 P4HA2-AS1 SLC22A5 SMAD3 ZNF652
Crohns Disease (2017)	5.70	17	9	20.0	-0.14	5.5e-01	AC034220.3 BACH2 FADS1 GSDMA KIAA1109 KIF11 LRRC32 MED24 NDFIP1 ORMDL3 P4HA2-AS1 PHF5A RP11-574K11.5 SLC22A5 SMAD3 STMN3 TNFSF4
Irritable Bowel Disease (IBD)	5.20	17	12	26.7	-0.10	6.6e-01	AC034220.3 BACH2 CASC3 GSDMA KIAA1109 KIF11 KRT222 LINGO4 LRRC32 MED24 NDFIP1 ORMDL3 P4HA2-AS1 RP11-574K11.5 SLC22A5 SMAD3 STMN3
Lung FEV1/FVC ratio	4.84	23	15	33.3	-0.79	5.7e-08	ADAM19 BACH2 D2HGDH DMWD EEFSEC GLDC IL18R1 IL1RL1 IL7R KIAA1432 MED24 MYBPH ORMDL3 P4HA2-AS1 RP11-396B14.2 RP11-574K11.5 RPS26 SLC22A5 SLC9A2 SMAD3 STAT6 ZNF652 ZNF76
Number of self-reported non-cancer illnesses	4.77	12	3	6.7	0.94	2.8e-07	D2HGDH EEFSEC IL1RL1 IQCH LINGO4 LRRC32 ORMDL3 P4HA2-AS1 PHF5A RP11-396B14.2 SLC22A5 ZNF652
Crohns Disease (2012)	4.63	10	6	13.3	-0.21	4.9e-01	AC034220.3 FADS1 GSDMA LRRC32 NDFIP1 ORMDL3 P4HA2-AS1 SLC22A5 SMAD3 STMN3
Taking other prescription medications	4.41	7	2	4.4	0.92	4.4e-04	AHI1 CTD-3074O7.5 D2HGDH IL1RL1 IQCH ORMDL3 ZNF652
Hypothyroidism (self reported)	3.25	12	5	11.1	-0.09	7.6e-01	AHI1 BACH2 CD247 FADS1 IL7R KIAA1109 PHF5A RERE RPS26 SPPL3 TLR1 UBAC2
Hypothyroidism/myxoedema (self-reported)	3.03	6	3	6.7	-0.14	7.6e-01	AHI1 BACH2 CD247 IL7R KIAA1109 RPS26
Ulcerative Colitis (UC)	2.89	9	4	8.9	0.00	1.0e+00	CASC3 GSDMA KIAA1109 KRT222 LINGO4 LRRC32 MED24 ORMDL3 SMAD3
Medication: Levothyroxine sodium	2.85	5	2	4.4	0.14	7.8e-01	AHI1 BACH2 FADS1 IL7R RPS26
Ulcerative Colitis	2.49	2	2	4.4	0.00	1.0e+00	KIAA1109 ORMDL3
Number of treatments/medications taken	2.49	4	1	2.2	0.97	2.6e-02	CLEC16A P4HA2-AS1 SLC9A2 ZNF652
Primary Biliary Cirrhosis	2.31	2	2	4.4	0.00	1.0e+00	IL7R ORMDL3
Forced expiratory volume in 1-second (FEV1), Best measure	2.21	10	6	13.3	-0.94	2.4e-06	ADAM19 AHI1 EEFSEC LINGO4 P4HA2-AS1 RP11-574K11.5 RPS26 SLC22A5 TRIM38 ZNF76
Long-standing illness, disability or infirmity	2.21	2	0	0.0	0.00	1.0e+00	IQCH ZNF652
HDL Cholesterol	2.16	5	2	4.4	0.02	9.8e-01	C17orf37 FADS1 KIF5A ORMDL3 ZNF76
Blood Platelet Count	2.16	17	16	35.6	0.44	6.0e-02	AC034220.3 DMWD EEFSEC FADS1 ING5 KIF1B KIF3A KIF5A NDFIP1 ORMDL3 P4HA2-AS1 PHF5A RP1-197B17.3 SIK2 SLC22A5 SPPL3 STMN3
Forced expiratory volume in 1-second (FEV1)	2.14	12	6	13.3	-0.95	5.6e-08	ADAM19 AHI1 CTD-3074O7.5 EEFSEC LINGO4 P4HA2-AS1 RP11-574K11.5 RPS26 SLC22A5 STMN3 TRIM38 ZNF76
Chest pain or discomfort	2.10	1	0	0.0	0.00	1.0e+00	IL1RL1
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.09	4	1	2.2	-0.90	1.0e-01	ADAM19 ORMDL3 STMN3 TRIM38
Hand grip strength (right)	2.04	6	4	8.9	-0.97	1.1e-05	AC034220.3 KIF1B P4HA2-AS1 SLC22A5 STAT6 ZNF76
Headache pain in last month	2.01	3	1	2.2	0.00	1.0e+00	DMWD RPS26 STAT6
Standing height	1.93	14	10	22.2	-0.76	4.5e-04	AC034220.3 AFF3 DMWD FADS1 IQCH P4HA2-AS1 PHF5A RERE SLC22A5 SPPL3 STAT6 TRIM38 ZNF652 ZNF76
Hand grip strength (left)	1.91	5	4	8.9	-0.99	4.3e-05	AC034220.3 KIF1B P4HA2-AS1 SLC22A5 ZNF76
Prostate Cancer	1.84	2	1	2.2	0.00	1.0e+00	EEFSEC STMN3
Vascular/heart problems diagnosed by doctor	1.84	9	5	11.1	-0.63	3.6e-02	AC034220.3 EEFSEC IQCH P4HA2-AS1 RERE SIK2 SLC22A5 SMAD3 ZNF652
Height	1.82	21	14	31.1	-0.58	3.2e-03	AC034220.3 AFF3 AHI1 CTD-3074O7.5 DMWD FADS1 IL1R1 IL1RL1 IQCH KIF11 KIF1B NDFIP1 P4HA2-AS1 PHF5A RERE SLC22A5 SMAD3 SPPL3 STAT6 ZNF652 ZNF76
Chronic bronchitis/emphysema (father)	1.82	1	0	0.0	0.00	1.0e+00	IQCH
Rheumatoid Arthritis	1.80	1	0	0.0	0.00	1.0e+00	ORMDL3
Lung FVC	1.80	14	9	20.0	-0.15	5.7e-01	AC034220.3 AHI1 C17orf37 CLEC16A IQCH KIF1B LINGO4 P4HA2-AS1 RIN3 RP11-574K11.5 RPS26 SLC22A5 SPPL3 STMN3
Triglycerides	1.78	2	2	4.4	0.00	1.0e+00	FADS1 KIF5A
Breast Cancer	1.72	6	3	6.7	0.63	1.3e-01	EFEMP2 KIF1B P4HA2-AS1 SIK2 SLC22A5 TLR1
Migraine (self-reported)	1.70	1	1	2.2	0.00	1.0e+00	STAT6
Forced expiratory volume in 1-second (FEV1), predicted	1.70	4	4	8.9	-0.97	1.2e-03	AC034220.3 P4HA2-AS1 SLC22A5 ZNF76
Lupus	1.66	1	1	2.2	0.00	1.0e+00	C17orf37
Illnesses of father: Heart disease	1.66	2	0	0.0	0.00	1.0e+00	SIK2 SMAD3
Medication: Blood pressure	1.66	4	0	0.0	0.73	1.6e-01	AC034220.3 P4HA2-AS1 SIK2 SLC22A5
Type 2 Diabetes (T2D) (2012)	1.65	2	1	2.2	0.00	1.0e+00	JAZF1 KIF11
Father's age at death	1.64	1	0	0.0	0.00	1.0e+00	SLC22A5
Comparative height size at age 10	1.64	9	7	15.6	-0.70	1.7e-02	AC034220.3 DMWD IQCH KIF11 P4HA2-AS1 SLC22A5 SMAD3 TRIM38 ZNF76
Hypertension (Self-reported)	1.64	8	4	8.9	0.58	7.6e-02	AC034220.3 EEFSEC P4HA2-AS1 RERE RPS26 SIK2 SLC22A5 ZNF652
Medication: Bendroflumethiazide	1.64	3	0	0.0	0.99	1.3e-02	AC034220.3 P4HA2-AS1 SLC22A5
High blood pressure	1.63	9	4	8.9	0.62	4.0e-02	AC034220.3 EEFSEC IQCH P4HA2-AS1 RERE RPS26 SIK2 SLC22A5 ZNF652
Gout (self-reported)	1.58	1	1	2.2	0.00	1.0e+00	KIF5A
Hair/balding pattern: Pattern 4	1.56	5	0	0.0	0.36	5.5e-01	CTD-2020K17.3 FADS1 IQCH KIF1B S100A11
Birth weight of first child	1.55	1	0	0.0	0.00	1.0e+00	RPS26
Myopia	1.55	2	0	0.0	0.00	1.0e+00	ORMDL3 STAT6
Medication: Blood pressure	1.53	2	2	4.4	0.00	1.0e+00	SIK2 ZNF652
Mouth/teeth dental problems: Mouth ulcers	1.52	1	0	0.0	0.00	1.0e+00	ORMDL3
Trunk predicted mass	1.50	8	8	17.8	-0.98	4.2e-07	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 STAT6 TRIM38 ZNF76
Vitamin and mineral supplements	1.49	1	1	2.2	0.00	1.0e+00	STAT6
Trunk fat-free mass	1.49	8	8	17.8	-0.98	4.3e-07	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 STAT6 TRIM38 ZNF76
Whole body water mass	1.48	8	7	15.6	-0.98	9.4e-07	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 STAT6 TRIM38 ZNF76
Number of operations (self-reported)	1.48	1	0	0.0	0.00	1.0e+00	IQCH
Medication for pain relief, constipation, heartburn	1.47	1	1	2.2	0.00	1.0e+00	STAT6
Diabetes diagnosed by doctor	1.47	2	1	2.2	0.00	1.0e+00	JAZF1 KIF11
Whole body fat-free mass	1.46	8	7	15.6	-0.98	8.6e-07	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 STAT6 TRIM38 ZNF76
Arm predicted mass (left)	1.45	7	7	15.6	-0.99	5.4e-07	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 TRIM38 ZNF76
Shortness of breath walking on level ground	1.44	1	0	0.0	0.00	1.0e+00	LRRC32
Impedance of arm (right)	1.43	11	7	15.6	0.64	1.8e-02	EEFSEC GSDMA KIF1B LRRC32 MED24 NDFIP1 PHF5A RIN3 RPS26 SMAD3 ZNF652
Arm predicted mass (right)	1.43	8	7	15.6	-0.98	2.9e-07	AC034220.3 MED24 P4HA2-AS1 RIN3 RPS26 SLC22A5 TRIM38 ZNF76
Medication: Simvastatin	1.42	1	0	0.0	0.00	1.0e+00	DMWD
Peak expiratory flow (PEF)	1.42	3	1	2.2	0.00	1.0e+00	ADAM19 SLC22A5 ZNF76
Arm fat-free mass (right)	1.42	8	7	15.6	-0.99	2.1e-07	AC034220.3 MED24 P4HA2-AS1 RIN3 RPS26 SLC22A5 TRIM38 ZNF76
Heart attack/myocardial infarction (self-reported)	1.42	1	0	0.0	0.00	1.0e+00	ZNF652
Bipolar Disorder or Schizophrenia	1.41	3	0	0.0	0.59	4.1e-01	CTD-3074O7.5 STAT6 TRIM38
Medication for cholesterol, blood pressure or diabetes	1.41	2	1	2.2	0.00	1.0e+00	SIK2 ZNF652
Medication: Allopurinol	1.41	1	1	2.2	0.00	1.0e+00	KIF5A
Fractured/broken bones in last 5 years	1.41	1	0	0.0	0.00	1.0e+00	IQCH
Cardiovascular Disease	1.40	7	2	4.4	0.28	5.5e-01	EEFSEC KRT222 RERE RPS26 SIK2 SLC22A5 ZNF652
Leg fat-free mass (left)	1.40	7	4	8.9	-0.90	4.6e-04	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 TRIM38 ZNF76
Leg predicted mass (left)	1.40	7	4	8.9	-0.98	2.2e-06	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 TRIM38 ZNF76
Medication: Aspirin	1.40	1	0	0.0	0.00	1.0e+00	SIK2
Basal metabolic rate	1.40	7	6	13.3	-0.99	7.4e-07	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 TRIM38 ZNF76
Arm fat-free mass (left)	1.39	7	7	15.6	-0.99	3.9e-07	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 TRIM38 ZNF76
Illnesses of father: None of the above (group 1)	1.38	1	0	0.0	0.00	1.0e+00	SMAD3
Leg predicted mass (right)	1.38	7	4	8.9	-0.98	1.8e-06	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 TRIM38 ZNF76
LDL Cholesterol	1.37	1	1	2.2	0.00	1.0e+00	FADS1
Heart attack	1.37	2	0	0.0	0.00	1.0e+00	KIF5A ZNF652
Impedance of arm (left)	1.37	10	5	11.1	0.56	7.6e-02	CTD-2020K17.3 EEFSEC KIF1B LRRC32 MED24 PHF5A RIN3 RPS26 SMAD3 ZNF652
Leg fat-free mass (right)	1.37	7	4	8.9	-0.98	1.8e-06	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 TRIM38 ZNF76
Age when periods started (menarche)	1.36	4	0	0.0	0.52	4.8e-01	EEFSEC IQCH RPS26 SPPL3
Multivitamins +/- minerals	1.36	1	0	0.0	0.00	1.0e+00	STAT6
Forced vital capacity (FVC)	1.36	8	3	6.7	-0.72	1.2e-02	AHI1 DMWD IQCH LINGO4 RP11-574K11.5 STMN3 TRIM38 ZNF76
Medication: Aspirin	1.35	1	0	0.0	0.00	1.0e+00	SIK2
Current tobacco smoking	1.34	1	1	2.2	0.00	1.0e+00	PHF5A
Fasting Glucose	1.33	1	1	2.2	0.00	1.0e+00	FADS1
Forced vital capacity (FVC), Best measure	1.33	9	2	4.4	-0.86	2.8e-04	AHI1 CTD-3074O7.5 IQCH LINGO4 RP11-574K11.5 RPS26 STMN3 TRIM38 ZNF76
Diastolic blood pressure, automated reading	1.33	5	1	2.2	0.58	3.1e-01	AC034220.3 P4HA2-AS1 RERE RPS26 ZNF652
Medication: Metformin	1.30	1	0	0.0	0.00	1.0e+00	KIF11
Diabetes (self-reported)	1.30	2	1	2.2	0.00	1.0e+00	JAZF1 KIF11
Medication: Paracetamol	1.30	1	1	2.2	0.00	1.0e+00	STAT6
Birth weight	1.30	2	1	2.2	0.00	1.0e+00	KIF11 SIK2
Medication: Ibuprofen	1.30	1	1	2.2	0.00	1.0e+00	STAT6
Smoking Status	1.29	4	2	4.4	0.21	7.9e-01	IQCH PHF5A RPS26 ZNF652
Type 2 Diabetes (T2D) (2018)	1.29	2	1	2.2	0.00	1.0e+00	JAZF1 KIF11
Pulse rate, automated reading	1.28	3	1	2.2	0.00	1.0e+00	FADS1 RPS26 SIK2
Sitting height	1.27	8	6	13.3	-0.83	1.4e-03	AC034220.3 DMWD P4HA2-AS1 SLC22A5 STAT6 TRIM38 ZNF652 ZNF76
Medication: Ibuprofen (e.g. Nurofen)	1.27	1	1	2.2	0.00	1.0e+00	STAT6
Mineral and other dietary supplements	1.27	1	0	0.0	0.00	1.0e+00	STAT6
Smoking status: Current	1.27	1	1	2.2	0.00	1.0e+00	PHF5A
Alcohol drinker status: Never	1.27	1	0	0.0	0.00	1.0e+00	SLC9A2
Had major operations	1.26	1	0	0.0	0.00	1.0e+00	ZNF652
Body Mass Index (BMI) (2010)	1.25	1	0	0.0	0.00	1.0e+00	SMAD3
Leg fat percentage (left)	1.25	7	1	2.2	0.39	3.9e-01	GSDMA IQCH KRT222 RERE SMAD3 STMN3 TRIM38
Angina	1.24	2	1	2.2	0.00	1.0e+00	AFF3 ZNF652
Leg fat percentage (right)	1.24	6	1	2.2	0.77	7.1e-02	IQCH KRT222 RERE SMAD3 STMN3 TRIM38
Age at first live birth	1.24	1	0	0.0	0.00	1.0e+00	RPS26
Qualifications: College or University degree	1.24	3	3	6.7	0.00	1.0e+00	AFF3 RPS26 TRIM38
Average weekly champagne plus white wine intake	1.23	1	0	0.0	0.00	1.0e+00	FADS1
Schizophrenia (2018)	1.22	2	1	2.2	0.00	1.0e+00	STAT6 TRIM38
Waist Hip Ratio (WHR)	1.22	7	0	0.0	0.19	6.3e-01	AFF3 DMWD GSDMA IQCH MED24 RP11-396B14.2 SIK2
Past tobacco smoking	1.21	3	1	2.2	0.00	1.0e+00	GLDC IQCH RPS26
Fluid intelligence score	1.21	2	0	0.0	0.00	1.0e+00	AFF3 RPS26
Comparative body size at age 10	1.21	3	1	2.2	0.00	1.0e+00	IQCH SMAD3 ZNF652
Impedance of whole body	1.21	8	5	11.1	0.33	4.3e-01	EEFSEC KIF1B LRRC32 MED24 PHF5A RIN3 RPS26 ZNF652
Reason for reducing amount of alcohol drunk: Health precaution	1.20	1	0	0.0	0.00	1.0e+00	RPS26
High cholesterol (Self-reported)	1.20	1	0	0.0	0.00	1.0e+00	FADS1
Ever had bowel cancer screening	1.19	1	0	0.0	0.00	1.0e+00	SIK2
Number of live births	1.18	1	1	2.2	0.00	1.0e+00	FADS1
Pain experienced in last month	1.18	2	0	0.0	0.00	1.0e+00	RPS26 STAT6
Smoking status: Previous	1.17	1	0	0.0	0.00	1.0e+00	IQCH
Weight	1.16	9	5	11.1	-0.47	1.2e-01	AC034220.3 FLG IQCH P4HA2-AS1 RPS26 SLC22A5 SMAD3 TRIM38 ZNF76
Angina (self-reported)	1.16	1	0	0.0	0.00	1.0e+00	ZNF652
Seen doctor (GP) for nerves, anxiety, tension or depression	1.14	1	0	0.0	0.00	1.0e+00	CTD-3074O7.5
Tense / 'highly strung'	1.12	2	0	0.0	0.00	1.0e+00	PHF5A RERE
Neuroticism (Nagel 2018)	1.11	1	0	0.0	0.00	1.0e+00	PHF5A
Depressed Affect (Nagel 2018)	1.10	2	0	0.0	0.00	1.0e+00	PHF5A RERE
Maternal smoking around birth	1.10	1	0	0.0	0.00	1.0e+00	PHF5A
Qualifications: None of the above	1.10	2	1	2.2	0.00	1.0e+00	RPS26 TRIM38
Pulse rate	1.10	1	1	2.2	0.00	1.0e+00	FADS1
Chronotype (morning person)	1.09	2	0	0.0	0.00	1.0e+00	KIAA1109 WDR36
Impedance of leg (left)	1.09	6	3	6.7	-0.43	4.0e-01	GPR182 RIN3 RPS26 S100A11 SLC22A5 ZNF652
Heel bone mineral density (BMD) T-score, automated (right)	1.09	3	2	4.4	0.00	1.0e+00	FADS1 RERE ZNF76
Impedance of leg (right)	1.08	4	3	6.7	-0.16	8.4e-01	GPR182 RIN3 RPS26 ZNF652
Knee pain experienced in last month	1.07	1	0	0.0	0.00	1.0e+00	RP11-396B14.2
Medication: Paracetamol	1.06	1	1	2.2	0.00	1.0e+00	STAT6
Verbal and Numeric Reasoning (VNR)	1.05	3	0	0.0	0.00	1.0e+00	AFF3 RPS26 TRIM38
Systolic blood pressure, automated reading	1.05	2	0	0.0	0.00	1.0e+00	DMWD STMN3
Blood Red Count	1.04	13	6	13.3	0.14	6.2e-01	AFF3 AHI1 BACH2 C17orf37 CTD-3074O7.5 FADS1 KIF11 KIF5A LINGO4 NDFIP1 RPS26 SPPL3 TLR1
Overall health rating	1.03	2	1	2.2	0.00	1.0e+00	CTD-3074O7.5 ZNF652
Waist circumference	1.02	3	2	4.4	0.00	1.0e+00	IQCH RPS26 SMAD3
Mouth/teeth dental problems: Dentures	1.02	1	0	0.0	0.00	1.0e+00	TRIM38
Body fat percentage	1.02	6	2	4.4	0.99	3.0e-04	FLG IQCH PHF5A RERE SMAD3 TRIM38
Alcohol intake frequency.	1.02	2	0	0.0	0.00	1.0e+00	RPS26 STAT6
Irritability	1.02	1	0	0.0	0.00	1.0e+00	FADS1
Trunk fat percentage	1.00	5	3	6.7	0.99	6.6e-04	FLG IQCH PHF5A SMAD3 TRIM38
Arm fat percentage (right)	1.00	4	2	4.4	0.99	6.0e-03	CTD-3074O7.5 IQCH PHF5A SMAD3
Systolic Blood Pressure	0.99	8	4	8.9	0.42	3.1e-01	CTD-2020K17.3 DMWD EEFSEC KIF11 RERE SIK2 SMAD3 ZNF652
Relative age of first facial hair	0.99	1	0	0.0	0.00	1.0e+00	SPPL3
Trunk fat mass	0.99	5	2	4.4	0.99	7.1e-04	FLG IQCH PHF5A SMAD3 TRIM38
Neuroticism score	0.99	1	0	0.0	0.00	1.0e+00	PHF5A
Leg fat mass (right)	0.99	5	3	6.7	0.64	2.5e-01	IQCH RERE RPS26 SMAD3 TRIM38
Leg fat mass (left)	0.99	8	3	6.7	0.34	4.1e-01	FLG GSDMA IQCH RERE RPS26 SMAD3 STMN3 TRIM38
Heel bone mineral density (BMD) T-score, automated (left)	0.97	3	0	0.0	0.00	1.0e+00	FADS1 RERE ZNF76
Hair/balding pattern: Pattern 3	0.97	1	0	0.0	0.00	1.0e+00	AC034220.3
Worry too long after embarrassment	0.97	2	0	0.0	0.00	1.0e+00	AHI1 IQCH
Friendships satisfaction	0.97	1	0	0.0	0.00	1.0e+00	EFEMP2
Schizophrenia (2014)	0.96	1	0	0.0	0.00	1.0e+00	STAT6
Hip circumference	0.96	5	1	2.2	0.22	6.4e-01	GSDMA IQCH SMAD3 STMN3 TRIM38
Whole body fat mass	0.96	7	2	4.4	0.68	9.0e-02	FLG IQCH PHF5A RPS26 SMAD3 STMN3 TRIM38
Arm fat percentage (left)	0.96	5	2	4.4	0.99	5.0e-04	CTD-3074O7.5 IQCH PHF5A SMAD3 TRIM38
Neuroticism	0.95	3	0	0.0	0.00	1.0e+00	AHI1 IQCH PHF5A
Supplements: Vitamin C	0.95	1	0	0.0	0.00	1.0e+00	ORMDL3
Arm fat mass (right)	0.93	4	2	4.4	0.50	5.0e-01	IQCH RPS26 SMAD3 TRIM38
Neck or shoulder pain in last month	0.93	1	0	0.0	0.00	1.0e+00	RPS26
Arm fat mass (left)	0.93	4	2	4.4	0.53	4.7e-01	IQCH RPS26 SMAD3 TRIM38
Worry (Nagel 2018)	0.92	1	0	0.0	0.00	1.0e+00	TRIM38
BMI	0.92	8	3	6.7	-0.11	7.7e-01	EEFSEC GSDMA IQCH PTP4A1 RPS26 SMAD3 STMN3 TLR1
Heel T-Score	0.91	10	5	11.1	-0.02	9.6e-01	BACH2 DMWD FADS1 IQCH KIF1B PHF5A RERE RIN3 RPS26 ZNF76
Body mass index (BMI)	0.91	3	1	2.2	0.00	1.0e+00	RPS26 SMAD3 TRIM38
Prospective memory result	0.91	1	0	0.0	0.00	1.0e+00	TRIM38
Intelligence (Savage-Jansen 2018)	0.87	2	2	4.4	0.00	1.0e+00	AFF3 RPS26
Qualifications: A levels/AS levels or equivalent	0.86	2	0	0.0	0.00	1.0e+00	RPS26 TRIM38
Mood swings	0.80	1	0	0.0	0.00	1.0e+00	PHF5A
Nervous feelings	0.78	1	0	0.0	0.00	1.0e+00	IQCH
Hair Pigment	0.17	7	5	11.1	-0.44	3.2e-01	AHI1 JAZF1 KIAA1432 KIF1B KIF5A RPS26 ZNF76

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Whole Blood	13	0.652	2.3
GTEx	Spleen	10	0.709	2.2
NTR	Blood	15	0.624	2.2
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	17	0.678	2.2
The Cancer Genome Atlas	Stomach Adenocarcinoma	8	0.475	2.2
GTEx	Brain Nucleus accumbens basal ganglia	6	0.694	2.1
GTEx	Brain Putamen basal ganglia	4	0.641	2.1
GTEx	Breast Mammary Tissue (Male)	6	0.503	2.1
GTEx	Cells Transformed fibroblasts	23	0.548	2.1
GTEx	Colon Transverse	10	0.484	2.1
GTEx	Heart Atrial Appendage	7	0.443	2.1
GTEx	Pancreas	8	0.490	2.1
GTEx	Skin Sun Exposed Lower leg	18	0.495	2.1
GTEx	Thyroid	19	0.475	2.1
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	19	0.464	2.1
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	5	0.452	2.1
The Cancer Genome Atlas	Lung Adenocarcinoma	13	0.442	2.1
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	9	0.542	2.1
The Cancer Genome Atlas	Rectum Adenocarcinoma	5	0.724	2.1
The Cancer Genome Atlas	Testicular Germ Cell Tumors	7	0.547	2.1
The Cancer Genome Atlas	Thyroid Carcinoma	28	0.543	2.1
GTEx	Adipose Visceral Omentum	9	0.442	2.0
GTEx	Artery Aorta	14	0.470	2.0
GTEx	Artery Tibial	20	0.532	2.0
GTEx	Brain Cerebellar Hemisphere	4	0.269	2.0
GTEx	Brain Cerebellum	6	0.303	2.0
GTEx	Brain Cortex	7	0.676	2.0
GTEx	Brain Frontal Cortex BA9	3	0.325	2.0
GTEx	Brain Hypothalamus	2	0.339	2.0
GTEx	Breast Mammary Tissue	10	0.507	2.0
GTEx	Colon Sigmoid	5	0.342	2.0
GTEx	Esophagus Mucosa	15	0.452	2.0
GTEx	Muscle Skeletal	13	0.450	2.0
GTEx	Pituitary	6	0.538	2.0
GTEx	Skin Not Sun Exposed Suprapubic	17	0.691	2.0
YFS	Blood	23	0.498	2.0
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	6	0.363	2.0
The Cancer Genome Atlas	Colon Adenocarcinoma	11	0.533	2.0
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	10	0.367	2.0
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	9	0.439	2.0
GTEx	Adipose Subcutaneous	9	0.258	1.9
GTEx	Breast Mammary Tissue (Female)	6	0.365	1.9
GTEx	Cells EBV-transformed lymphocytes	6	0.422	1.9
GTEx	Esophagus Muscularis	9	0.278	1.9
GTEx	Liver	3	0.418	1.9
GTEx	Lung	9	0.313	1.9
GTEx	Nerve Tibial	15	0.347	1.9
GTEx	Ovary	5	0.551	1.9
GTEx	Prostate	5	0.599	1.9
GTEx	Testis	15	0.475	1.9
METSIM	Adipose	18	0.390	1.9
ROSMAP	Brain Pre-frontal Cortex	20	0.455	1.9
CommonMind	Brain Pre-frontal Cortex	22	0.409	1.9
The Cancer Genome Atlas	Breast Invasive Carcinoma	21	0.477	1.9
The Cancer Genome Atlas	Glioblastoma Multiforme	6	0.587	1.9
The Cancer Genome Atlas	Brain Lower Grade Glioma	16	0.372	1.9
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	3	0.226	1.9
The Cancer Genome Atlas	Prostate Adenocarcinoma	17	0.368	1.9
The Cancer Genome Atlas	Skin Cutaneous Melanoma	2	0.374	1.9
GTEx	Adrenal Gland	5	0.343	1.8
GTEx	Esophagus Gastroesophageal Junction	5	0.346	1.8
GTEx	Heart Left Ventricle	4	0.261	1.8
GTEx	Stomach	5	0.344	1.8
GTEx	Uterus	1	0.176	1.8
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	6	0.547	1.8
The Cancer Genome Atlas	Esophageal Carcinoma	3	0.438	1.8
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	5	0.314	1.8
The Cancer Genome Atlas	Soft Tissue Sarcoma	2	0.187	1.8
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.394	1.8
GTEx	Artery Coronary	1	0.085	1.7
GTEx	Brain Caudate basal ganglia	3	0.326	1.7
GTEx	Brain Hippocampus	1	0.191	1.7
GTEx	Small Intestine Terminal Ileum	1	0.217	1.7
GTEx	Vagina	0	0.000	1.7